Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice

Cancer Immunology, Immunotherapy

Volumn 59, Issue 8, 2010, Pages 1247-1258

  Masuelli, Laura ^a   Marzocchella, Laura ^b   Focaccetti, Chiara ^b   Lista, Florigio ^c   Nardi, Alessandra ^b   Scardino, Antonio ^a   Mattei, Maurizio ^b   Turriziani, Mario ^b   Modesti, Mauro ^a   Forni, Guido ^d   Schlom, Jeffrey ^e   Modesti, Andrea ^b   Bei, Roberto ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Centro Studi e Ricerche Sanità e Veterinaria Esercito   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccine; Intratumoral vaccination; Recombinant vaccinia virus; Serum antibodies

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER INHIBITION; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; EARLY INTERVENTION; HUMORAL IMMUNITY; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS RECOMBINANT; WILD TYPE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL PROLIFERATION; FEMALE; GENE TRANSFER TECHNIQUES; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NIH 3T3 CELLS; RATS; RECEPTOR, ERBB-2; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 77953230205     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0850-0     Document Type: Article

References (52)

1. BL Jacobs JO Langland KV Kibler, et al. 2009 Vaccinia virus vaccines: past, present and future Antiviral Res 84 1 13 10.1016/j.antiviral.2009.06.006 1:CAS:528:DC%2BD1MXhtV2rs7jP 19563829
2. RB Kennedy IG Ovsyannikova RM Jacobson GA Poland 2009 The immunology of smallpox vaccines Curr Opin Immunol 21 314 320 10.1016/j.coi.2009.04.004 1:CAS:528:DC%2BD1MXnsFOlsbs%3D 19524427
3. S Essajee HL Kaufman 2004 Poxvirus vaccines for cancer and HIV therapy Expert Opin Biol Ther 4 575 588 10.1517/14712598.4.4.575 1:CAS:528: DC%2BD2cXis1OqtrY%3D 15102606 (Pubitemid 38480556)
4. HL Kaufman 2003 The role of poxviruses in tumor immunotherapy Surgery 134 731 737 10.1016/S0039-6060(03)00294-0 14639347 (Pubitemid 37523955)
5. B Moss 1996 Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety Proc Natl Acad Sci U S A 93 11341 11348 10.1073/pnas.93.21.11341 1:CAS:528:DyaK28Xmtlagsrw%3D 8876137 (Pubitemid 26347123)
6. RJ Lechleider PM Arlen KY Tsang, et al. 2008 Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant Clin Cancer Res 14 5284 5291 10.1158/1078-0432.CCR-07-5162 1:CAS:528: DC%2BD1cXpslKns7g%3D 18698048
7. HL Kaufman S Kim-Schulze K Manson, et al. 2007 Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer J Transl Med 26 5 60 10.1186/1479-5876-5-60 (Pubitemid 351188981)
8. J Gulley AP Chen W Dahut, et al. 2002 Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer Prostate 53 109 117 10.1002/pros.10130 1:CAS:528:DC%2BD38XosFSks7w%3D 12242725
9. JL Marshall RJ Hoyer MA Toomey, et al. 2000 Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses J Clin Oncol 18 3964 3973 1:STN:280:DC%2BD3M%2Fnt1GisQ%3D%3D 11099326
10. SM Scholl JM Balloul G Le Goc, et al. 2000 Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer J Immunother 23 570 580 10.1097/00002371-200009000-00007 1:CAS:528: DC%2BD3cXntFCnu7c%3D 11001550
11. MJ Mastrangelo HC Maguire EC Lattime 2000 Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma Adv Exp Med Biol 465 391 400 10.1007/0-306-46817-4-34 1:CAS:528:DC%2BD3cXlsVGitr0%3D 10810643
12. RM Conry KO Allen S Lee, et al. 2000 Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine Clin Cancer Res 6 34 41 1:CAS:528:DC%2BD3cXhtVequrc%3D 10656429
13. RM Conry MB Khazaeli MN Saleh, et al. 1999 Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration Clin Cancer Res 5 2330 2337 1:CAS:528:DyaK1MXmsFyjsrY%3D 10499601
14. MK Wallack M Sivanandham CM Balch, et al. 1998 Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial J Am Coll Surg 187 69 77 10.1016/S1072-7515(98)00097-0 1:STN:280:DyaK1czitFCltw%3D%3D 9660028 (Pubitemid 28303535)
15. S Kim-Schulze HS Kim A Wainstein, et al. 2008 Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer J Immunol 181 8112 8119 1:CAS:528:DC%2BD1cXhtl2gsLrN 19018004
16. HL Kaufman S Cohen K Cheung, et al. 2006 Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors Hum Gene Ther 17 239 244 10.1089/hum.2006.17.239 1:CAS:528: DC%2BD28XpvV2hsw%3D%3D 16454657 (Pubitemid 43263093)
17. H Hörig HL Kaufman 2003 Local delivery of poxvirus vaccines for melanoma Semin Cancer Biol 13 417 422 10.1016/j.semcancer.2003.09.005 15001160 (Pubitemid 38156133)
18. HL Kaufman G DeRaffele J Divito, et al. 2001 A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma Hum Gene Ther 12 1459 1480 10.1089/104303401750298616 1:STN:280:DC%2BD3MvnsVWksg%3D%3D 11485637 (Pubitemid 32881351)
19. LG Gomella MJ Mastrangelo PA McCue HC Maguire Jr SG Mulholland EC Lattime 2001 Phase I study of intravescical vaccinia virus as a vector for gene therapy of bladder cancer J Urol 166 1291 1295 10.1016/S0022-5347(05)65755-2 1:CAS:528:DC%2BD3MXptVKks7c%3D 11547060
20. C Kudo-Saito J Schlom JW Hodge 2005 Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses Clin Cancer Res 11 2416 2426 10.1158/1078-0432.CCR-04-1380 1:CAS:528:DC%2BD2MXisFais74%3D 15788693 (Pubitemid 40490203)
21. C Kudo-Saito J Schlom JW Hodge 2004 Intratumoral vaccination and diversified subcutaneous/intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules Clin Cancer Res 10 1090 1099 10.1158/1078-0432.CCR-03-0145 1:CAS:528:DC%2BD2cXhtFCgu7k%3D 14871989 (Pubitemid 38198911)
22. MR Crittenden U Thanarajasingam RG Vile MJ Gough 2005 Intratumoral immunotherapy: using the tumour against itself Immunology 114 11 22 10.1111/j.1365-2567.2004.02001.x 1:CAS:528:DC%2BD2MXlt1KrsA%3D%3D 15606790 (Pubitemid 40030288)
23. HL Kaufman DW Kim G Deraffele J Mitcham RS Coffin S Kim-Schulze 2010 Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma Ann Surg Oncol 17 718 730 10.1245/s10434-009-0809-6 19915919
24. AS Yang CE Monken EC Lattime 2003 Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen Cancer Res 63 6956 6961 1:CAS:528:DC%2BD3sXosVGnsLs%3D 14583497
25. P Wright C Zheng T Moyana J Xiang 1998 Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression Cancer Gene Ther 5 371 379 1:CAS:528:DyaK1MXmt1Kntg%3D%3D 9917092
26. K Boggio G Nicoletti E Di Carlo, et al. 1998 Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice J Exp Med 188 589 596 10.1084/jem.188.3.589 1:CAS:528: DyaK1cXltFyjsL0%3D 9687535 (Pubitemid 28369147)
27. S Rovero A Amici E Di Carlo, et al. 2000 DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice J Immunol 165 5133 5142 1:CAS:528:DC%2BD3cXnvVOntr8%3D 11046045
28. F Cavallo R Offringa SH van der Burg G Forni CJ Melief 2006 Vaccination for treatment and prevention of cancer in animal models Adv Immunol 90 175 213 10.1016/S0065-2776(06)90005-4 1:CAS:528:DC%2BD1cXhsVCjurs%3D 16730264 (Pubitemid 43765801)
29. SD Allen JT Garrett SV Rawale, et al. 2007 Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo J Immunol 179 472 482 1:CAS:528:DC%2BD2sXmsF2gsbw%3D 17579068
30. P Gallo S Dharmapuri M Nuzzo, et al. 2007 Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice Int J Cancer 120 574 584 10.1002/ijc.22274 1:CAS:528: DC%2BD28XhtlGqsrfP 17096348 (Pubitemid 44969029)
31. JM Park M Terabe JC Steel, et al. 2008 Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine Cancer Res 68 1979 1987 10.1158/0008-5472.CAN-07-5688 1:CAS:528:DC%2BD1cXjtFOhtrk%3D 18339880 (Pubitemid 351416585)
32. P Nanni L Landuzzi G Nicoletti, et al. 2004 Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent J Immunol 173 2288 2296 1:CAS:528:DC%2BD2cXmt1Olsr8%3D 15294941 (Pubitemid 39063084)
33. L Masuelli C Focaccetti V Cereda, et al. 2007 Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors Int J Oncol 30 381 392 1:CAS:528:DC%2BD2sXhvFyrur0%3D 17203220
34. CI Bargmann MC Hung RA Weinberg 1986 The neu oncogene encodes an epidermal growth factor receptor-related protein Nature 319 226 230 10.1038/319226a0 1:CAS:528:DyaL28XhtVensLk%3D 3945311
35. E Di Marco JH Pierce CL Knicley PP Di Fiore 1990 Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene Mol Cell Biol 10 3247 3252 1971420
36. R Bei A Budillon L Masuelli, et al. 2004 Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients J Pathol 204 317 325 10.1002/path.1642 1:CAS:528:DC%2BD2cXhtVenur7F 15476268 (Pubitemid 39430092)
37. R Bei J Kantor SV Kashmiri S Abrams J Schlom 1994 Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA J Immunother Emphasis Tumor Immunol 16 275 282 1:CAS:528:DyaK2MXjs12lurs%3D 7881636
38. R Bei V Guptill L Masuelli, et al. 1998 The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice J Immunother 21 159 169 10.1097/00002371-199805000-00001 1:CAS:528:DyaK1cXjsVWisLw%3D 9610907
39. AM Gown MC Willingham 2002 Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3 J Histochem Cytochem 50 449 454 1:CAS:528:DC%2BD38Xis1Wnt74%3D 11897797
40. L Masuelli P Trono L Marzocchella, et al. 2008 Intercalated disk remodeling in delta-sarcoglycan-deficient hamsters fed with an alpha-linolenic acid-enriched diet Int J Mol Med 21 41 48 1:CAS:528:DC%2BD1cXhtVOltL8%3D 18097614
41. CL Vogel MA Cobleigh D Tripathy, et al. 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D 11821453 (Pubitemid 34111379)
42. R Nahta FJ Esteva 2006 Herceptin: mechanisms of action and resistance Cancer Lett 232 123 138 10.1016/j.canlet.2005.01.041 1:CAS:528: DC%2BD28XhtFWhurg%3D 16458110 (Pubitemid 43170962)
43. ML Disis DR Wallace TA Gooley, et al. 2009 Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer J Clin Oncol 27 4685 4692 10.1200/JCO.2008.20.6789 1:CAS:528:DC%2BD1MXhtlGgtbnK 19720923
44. ML Disis K Schiffman 2001 Cancer vaccines targeting the HER2/neu oncogenic protein Semin Oncol 28 6 Suppl 18 12 20 10.1053/sonc.2001.29721 1:CAS:528:DC%2BD38XhtFOitLs%3D 11774201
45. EY Denkers CC Badger JA Ledbetter ID Bernstein 1985 Influence of antibody isotype on passive serotherapy of lymphoma J Immunol 135 2183 2186 1:STN:280:DyaL2M3mt12htQ%3D%3D 2862210
46. P Nanni G Nicoletti C De Giovanni, et al. 2001 Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice J Exp Med 194 1195 1205 10.1084/jem.194.9.1195 1:CAS:528:DC%2BD3MXot12msLY%3D 11696586 (Pubitemid 33055039)
47. S Rolla C Nicolo S Malinarich M Orsini, et al. 2006 Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice J Immunol 177 7626 7633 1:CAS:528:DC%2BD28Xht1WrsL%2FN 17114432
48. P Matzinger 2002 The danger model: a renewed sense of self Science 296 301 305 10.1126/science.1071059 1:CAS:528:DC%2BD38XjtVWiurk%3D 11951032 (Pubitemid 34303674)
49. R Bei L Masuelli C Palumbo, et al. 2009 A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth Cancer Lett 281 8 23 10.1016/j.canlet.2008.11.009 1:CAS:528:DC%2BD1MXmvFyqtLw%3D 19091462
50. L Aurisicchio D Peruzzi A Conforti, et al. 2009 Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9 Clin Cancer Res 15 1575 1584 10.1158/1078-0432.CCR-08-2628 1:CAS:528:DC%2BD1MXisVWku7c%3D 19240169
51. C Mastini PD Becker M Iezzi, et al. 2008 Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice Curr Cancer Drug Targets 8 230 242 10.2174/156800908784293604 1:CAS:528:DC%2BD1cXmtFamtL4%3D 18473736 (Pubitemid 351666859)
52. DJ Betting RE Yamada K Kafi, et al. 2009 Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma J Immunother 32 622 631 10.1097/CJI.0b013e3181ab23f1 1:CAS:528:DC%2BD1MXnsFKkt7g%3D 19483647